BackARCA biopharma Overview

ARCA biopharma Current Cash

Track ARCA biopharma's current cash ($50M) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Current Cash
$49.52M
↓ 40.75% YoYΔ $-34.05M vs prior year quarter

Peer average

Loading

ARCA biopharma Current Cash History

Loading

ARCA biopharma vs. peers: Current Cash Comparison

Loading

ARCA biopharma Cash Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

ARCA biopharma (ABIO) FAQ

ARCA biopharma (ABIO) currently reports a current cash of $50M as of March 2026. That compares with $84M in the prior-year period — down 40.7% year over year. Use the charts on this page to explore ARCA biopharma's current cash history and peer comparisons.

ARCA biopharma's current cash decreased from $84M to $50M — a 40.7% year-over-year decrease (period ending March 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

ARCA biopharma reported $50M in current cash as of March 2026. That compares with $84M in the prior-year period — down 40.7% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current current cash of $50M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for ARCA biopharma, and consider following ABIO for alerts when major investors trade the stock.

ARCA biopharma is classified in the Healthcare sector. On current cash, it currently shows $50M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing ABIO with unrelated industries.